Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

Direct Payment

$145,833.00

Development of novel tumor-specific, brain-penetrating nanomedicines to target high-grade gliomas

EF 2014-15

Résumé
Brain tumors are associated with very poor survival because many commonly used drugs to treat cancer are not able to enter the brain. The most aggressive types of brain cancer cells invade into the surrounding normal brain and are impossible to remove by surgery. These cells are protected inside the brain from cancer drugs by the blood brain barrier (BBB), leading to inevitable regrowth of the tumor and ultimately to the death of the patient. This leaves us with an urgent need to develop therapeutics that can effectively enter the brain, target and kill cancer cells. By identifying very specific and unique molecules or "signatures" that distinguish brain cancer cells, we should be able to target only the tumor cells without harming normal brain tissues. A protein called B/bDg is an ideal target because it is present only in human brain cancer cells, and is absent from normal brain cells. Here, we propose to generate "smart" peptides (small proteins) that can bind specifically to the B/bDg protein on brain tumor cells. These smart peptides will then be chemically fused onto nanoparticles (particles between 1 to 100 nm in size) with BBB-penetrating capabilities for delivery into the brain. Level of brain entry will be evaluated using our unique brain culture model and in animals. These nanoparticles will then be loaded with chemotherapeutic drugs, and their ability to selectively kill brain cancer cells will be assessed first in cultured cells, and then in animals. Ultimately, the ability of these agents to increase survival in tumor-bearing mice will be evaluated. These novel nanomedicines can potentially spearhead the development of new therapeutic agents that can substantially improve treatment of brain cancer. We hope that our discoveries will translate into improved outcomes and enhanced quality of lives of brain cancer patients.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
318411
Name
Cho Choi-Fong
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Development of novel tumor-specific, brain-penetrating nanomedicines to target high-grade gliomas
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$145,833
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Blood Brain Barrier; Brain Cancer (Glioma); Brevican Or B/Bdg; Drug Delivery; Nanomedicine; One-Bead-One-Compound (Oboc) Library; Targeting Peptide
Abstract
Brain tumors are associated with very poor survival because many commonly used drugs to treat cancer are not able to enter the brain. The most aggressive types of brain cancer cells invade into the surrounding normal brain and are impossible to remove by surgery. These cells are protected inside the brain from cancer drugs by the blood brain barrier (BBB), leading to inevitable regrowth of the tumor and ultimately to the death of the patient. This leaves us with an urgent need to develop therapeutics that can effectively enter the brain, target and kill cancer cells. By identifying very specific and unique molecules or "signatures" that distinguish brain cancer cells, we should be able to target only the tumor cells without harming normal brain tissues. A protein called B/bDg is an ideal target because it is present only in human brain cancer cells, and is absent from normal brain cells. Here, we propose to generate "smart" peptides (small proteins) that can bind specifically to the B/bDg protein on brain tumor cells. These smart peptides will then be chemically fused onto nanoparticles (particles between 1 to 100 nm in size) with BBB-penetrating capabilities for delivery into the brain. Level of brain entry will be evaluated using our unique brain culture model and in animals. These nanoparticles will then be loaded with chemotherapeutic drugs, and their ability to selectively kill brain cancer cells will be assessed first in cultured cells, and then in animals. Ultimately, the ability of these agents to increase survival in tumor-bearing mice will be evaluated. These novel nanomedicines can potentially spearhead the development of new therapeutic agents that can substantially improve treatment of brain cancer. We hope that our discoveries will translate into improved outcomes and enhanced quality of lives of brain cancer patients.
Competitiondate
201411
Approvedterm2
2 yrs 11 mths
Pinamesdelim
Cho, Choi-Fong
Approvedterm
2 ans 11 mois
Cihrcontribution2
~ $145,833~ $0~